Physician profile
Vanessa E Ngakeng
NPI 1326264888
$4,494.94
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,133 · 2020: $2,349 · 2021: $13.43.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $2,058.57 | 2019-2021 | |
| Biotissue Holdings INC. | $1,345.06 | 2019 | |
| Allergan, INC. | $252.85 | 2020 | |
| Eyepoint US, INC. | $250.00 | 2019 | |
| Kala Pharmaceuticals, INC. | $184.20 | 2019 | |
| Sun Pharmaceutical Industries INC. | $164.34 | 2019-2020 | |
| Alcon Vision LLC | $85.12 | 2019 | |
| New World Medical,INC. | $49.92 | 2019-2020 | |
| Glaukos Corporation | $36.94 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $32.65 | 2019 | |
| Shire North American Group INC | $20.91 | 2019 | |
| Aerie Pharmaceuticals, INC. | $14.38 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Ngakeng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.